MedPath

MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease

Completed
Conditions
Alzheimer Disease
Registration Number
NCT05402566
Lead Sponsor
University of Aarhus
Brief Summary

Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1) optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in Alzheimer's patients and healthy controls.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Deuterium Metabolic ImagingUp to 150 mins after 2H-glucose ingestion

Lactate/glx ratio in the posterior cingulum (sub-study 2).

Secondary Outcome Measures
NameTimeMethod
Deuterium Metabolic ImagingUp to 150 mins after 2H-glucose ingestion

Simpler DMI quantifications, including reference to external phantoms and internal reference, in the same regions defined in primary outcomes.

Cognitive tests from the records (sub study 2)At time of Deuterium Metabolic Imaging

Addenbrooke's Cognitive Examination (0-100, 100 is best)

Cerebrospinal fluid biochemistry from the records (sub study 2)At time of Deuterium Metabolic Imaging

Amyloid

FDG-PET from the records (sub study 2)At time of Deuterium Metabolic Imaging

Brain glucose uptake

Blood samplesUp to 150 mins after 2H-glucose ingestion

2H-enrichment

Trial Locations

Locations (1)

Aarhus University

🇩🇰

Aarhus, Denmark

Aarhus University
🇩🇰Aarhus, Denmark

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.